A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis. / Sinkeviciute, Dovile; Groen, Solveig Skovlund; Sun, Shu; Manon-Jensen, Tina; Aspberg, Anders; Onnerfjord, Patrik; Bay-Jensen, Anne-Christine; Kristensen, Salome; Nielsen, Signe Holm.
I: Scientific Reports, Bind 10, Nr. 1, 13541, 2020.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis
AU - Sinkeviciute, Dovile
AU - Groen, Solveig Skovlund
AU - Sun, Shu
AU - Manon-Jensen, Tina
AU - Aspberg, Anders
AU - Onnerfjord, Patrik
AU - Bay-Jensen, Anne-Christine
AU - Kristensen, Salome
AU - Nielsen, Signe Holm
PY - 2020
Y1 - 2020
N2 - Psoriatic arthritis (PsA) is a chronic musculoskeletal inflammatory disease found in up to 30% of psoriasis patients. Prolargin-an extracellular matrix (ECM) protein present in cartilage and tendon-has been previously shown elevated in serum of patients with psoriasis. ECM protein fragments can reflect tissue turnover and pathological changes; thus, this study aimed to develop, validate and characterize a novel biomarker PROM targeting a matrix metalloproteinase (MMP)-cleaved prolargin neo-epitope, and to evaluate it as a biomarker for PsA. A competitive ELISA was developed with a monoclonal mouse antibody; dilution- and spiking-recovery, inter- and intra-variation, and accuracy were evaluated. Serum levels were evaluated in 55 healthy individuals and 111 patients diagnosed with PsA by the CASPAR criteria. Results indicated that the PROM assay was specific for the neo-epitope. Inter- and intra- assay variations were 11% and 4%, respectively. PROM was elevated (p=0.0003) in patients with PsA (median: 0.24, IQR: 0.19-0.31) compared to healthy controls (0.18; 0.14-0.23) at baseline. AUROC for separation of healthy controls from PsA patients was 0.674 (95% CI 0.597-0.744, P
AB - Psoriatic arthritis (PsA) is a chronic musculoskeletal inflammatory disease found in up to 30% of psoriasis patients. Prolargin-an extracellular matrix (ECM) protein present in cartilage and tendon-has been previously shown elevated in serum of patients with psoriasis. ECM protein fragments can reflect tissue turnover and pathological changes; thus, this study aimed to develop, validate and characterize a novel biomarker PROM targeting a matrix metalloproteinase (MMP)-cleaved prolargin neo-epitope, and to evaluate it as a biomarker for PsA. A competitive ELISA was developed with a monoclonal mouse antibody; dilution- and spiking-recovery, inter- and intra-variation, and accuracy were evaluated. Serum levels were evaluated in 55 healthy individuals and 111 patients diagnosed with PsA by the CASPAR criteria. Results indicated that the PROM assay was specific for the neo-epitope. Inter- and intra- assay variations were 11% and 4%, respectively. PROM was elevated (p=0.0003) in patients with PsA (median: 0.24, IQR: 0.19-0.31) compared to healthy controls (0.18; 0.14-0.23) at baseline. AUROC for separation of healthy controls from PsA patients was 0.674 (95% CI 0.597-0.744, P
KW - RICH REPEAT PROTEIN
KW - PRELP
KW - DIAGNOSIS
KW - DISEASE
KW - TIMP-1
KW - DELAY
U2 - 10.1038/s41598-020-70327-0
DO - 10.1038/s41598-020-70327-0
M3 - Journal article
C2 - 32782251
VL - 10
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 13541
ER -
ID: 248027734